Volkan Tekin

An in-vivo pilot study into the effects of FDG-mNP in cancer in mice

Purpose Previously, fluorodeoxy glucose conjugated magnetite nanoparticles (FDG-mNPs) injected into cancer cells in conjunction with the application of magnetic hyperthermia have shown promise in new FDG-mNPs applications. The aim of this study was to determine potential toxic or unwanted effects involving both tumour cells and normal tissue in other organs when FDG-mNPs are administered intravenously or intratumourally in mice. Materials and methods FDG-mNPs were synthesized. A group of six prostate-tumour bearing mice were injected with 23.42 mg/ml FDG-mNPs (intravenous injection, n = 3; intratumoural injection into the prostate tumour, n = 3). Mice were euthanized and histological sampling of tissue was conducted for the prostate tumour, as well as for lungs, lymph nodes, liver, kidneys, spleen, and brain, at 1 hour (n = 2) and 7 days (n = 4) post-injection. A second group of two normal (non-cancerous) mice received the same injection intravenously into the tail vein and were euthanised at 3 and 6 months post-injection, respectively, to investigate if FDG-mNPs remained in organs at those time points. Results In prostate-tumour bearing mice, FDG-mNPs concentrated in the prostate tumour, while relatively small amounts were found in the organs of other tissues, particularly the spleen and the liver; FDG-mNP concentrations decreased over time in all tissues. In normal mice, no detrimental effects were found in either mouse at 3 or 6 months. Conclusion Intravenous or intratumoural FDG-mNPs can be safely administered for effective cancer cell destruction. Further research on the clinical utility of FDG-mNPs will be conducted by applying hyperthermia in conjunction with FDG-mNPs in mice.

PLGA encapsulation effect on Bioquin-HMPAO: radiolabeling and in vitro behaviour on brain and lung cancer cells

Bioquin-HMPAO (BH) was previously investigated as a novel brain imaging agent by in vivo biodistribution studies. Present studies are carried out to explore radiolabeling and in vitro behaviour evaluation of poly (lactic-co-glycolic acid) (PLGA) encapsulated BH nanocapsules (BH-PLGA NCs). BH-PLGA NCs were characterized utilizing dynamic light scattering and scanning electron microscope. Encapsulation effect on radiolabeling with 99mTc was examined by stability and lipophilicity studies and effect on in vitro behaviour of 99mTc-BH was evaluated by incorporation studies on DAOY, U87-MG and A549 cells. It is observed that PLGA encapsulation has a positive and reinforcement effect.

Hyaluronic acid-modified [19F]FDG-conjugated magnetite nanoparticles: in vitro bioaffinities and HPLC analyses in organs

In this study, we designed and synthesized [19F]FDG-(2-deoxy-2-[fluorine-19]fluoro-d-glucose) conjugated iron oxide magnetic nanoparticles ([19F]FDG-MNPs) for hybrid imaging and hyperthermia treatment. MNPs were synthesized, silica coated, and fabricated with TEOS (tetraethyl orthosilicate). They were then covered with hyaluronic acid (HA) to enhance their bioavailability. The modified MNPs were conjugated with [19F]FDG and optically labeled with ICG (indocyanine green). The in vitro bioaffinities were surveyed in MCF7 and PC3 cell lines. In vivo bioaffinies were determined using Sprague–Dawley rats.

PLGA encapsulation and radioiodination of indole-3-carbinol: investigation of anticancerogenic effects against MCF7, Caco2 and PC3 cells by in vitro assays

Encapsulation with PLGA of I3C and radioiodination have been performed. Anticancerogenic effects of I3C and I3C-PLGA have been investigated utilizing in vitro methods on breast adenocarcinoma epithelial (MCF7), colon adenocarcinoma epithelial (Caco2), prostate carcinoma epithelial (PC3) cells. Characterization of I3C-PLGA have been performed with DLS method and SEM analysis. I3C and I3C-PLGA compounds have been radiolabeled in high yields with 131I which is widely used for diagnosis and treatment in Nuclear Medicine. All experimental results demonstrated that radioiodinated compounds are promising in order to be used in Nuclear Medicine as well as present study contributed previously reported studies.

Investigation of 99mTc Labeled Clioquinol Derivative on Amyloid Plaque Specifity by Using Animal Model of Alzheimer’s Disease

Objective: Alzheimer’s disease (AD), which comes up an important problem due to the aging population, has two hallmarks defined as amyloid plaques and neurofibrillary tangles. Despite the fact that AD affects a wide audience adversely, definitive diagnosis of AD still requires postmortem examination of the brain through histological staining of these hallmarks. Nowadays, these two hallmarks are playing crucial role in researches for diagnosis and treatment of AD. In addition, deficiency of AD diagnosis agents and limitation of assessing the blood-brain barrier (BBB) are main reasons of the current researches focusing on brain agents with plaque or tangle imaging potential. Metal-protein attenuating compounds (MPACs) such as clioquinol and cloxyquin have a great increasing promise on amyloid plaques. Yurt Kilcar et al. radiolabeled Bioquin-Hexa methyl propylene amine oxime (HMPAO) with 99mTc (99mTc-Bioquin-HMPAO) and evaluated the biodistribution on healthy male Balb/C mice (unpublished data). In current study, it is aimed to investigate amyloid plaque specifity of the 99mTc-BioquinHMPAO by using biodistribution studies on animal model of AD. Methods: Bioquin-HMPAO was labeled with 99mTc according to previous study. In accordance with the objectives of the study, animal model of AD created on healthy male Sprague Dawley rats with intrahippocampal stereotaxic injection of amyloid beta 1-42 (Aβ1-42). Intrahippocampal administration was applied to the CA1 area of hippocampus bilaterally (Aβ142 to the left side and PBS to the right side as control). Additionally, healthy male Sprague Dawley rats were utilized as naïve group. Twenty days after surgery, biodistribution studies of 99mTc-Bioquin-HMPAO on animal model of AD and control group Susanne Granegger1, Lindsay Brammen2, Helmut Sinzinger1 1Institute ATHOS, Atherosclerosis Research, Vienna, Austria 2Vienna Medical University, Department of Nuclear Medicine, Vienna, Austria Elevated Lipoprotein(A) Impairs Platelet Radiolabeling Yield

INVESTIGATION OF 99MTC-LABELED CLIOQUINOL DERIVATIVE ON AMYLOID PLAQUE SPECIFICITY BY USING AN ANIMAL MODEL OF ALZHEIMER'S DISEASE

Objective: Alzheimer’s disease (AD), which comes up an important problem due to the aging population, has two hallmarks defined as amyloid plaques and neurofibrillary tangles. Despite the fact that AD affects a wide audience adversely, definitive diagnosis of AD still requires postmortem examination of the brain through histological staining of these hallmarks. Nowadays, these two hallmarks are playing crucial role in researches for diagnosis and treatment of AD. In addition, deficiency of AD diagnosis agents and limitation of assessing the blood-brain barrier (BBB) are main reasons of the current researches focusing on brain agents with plaque or tangle imaging potential. Metal-protein attenuating compounds (MPACs) such as clioquinol and cloxyquin have a great increasing promise on amyloid plaques. Yurt Kilcar et al. radiolabeled Bioquin-Hexa methyl propylene amine oxime (HMPAO) with 99mTc (99mTc-Bioquin-HMPAO) and evaluated the biodistribution on healthy male Balb/C mice (unpublished data). In current study, it is aimed to investigate amyloid plaque specifity of the 99mTc-BioquinHMPAO by using biodistribution studies on animal model of AD. Methods: Bioquin-HMPAO was labeled with 99mTc according to previous study. In accordance with the objectives of the study, animal model of AD created on healthy male Sprague Dawley rats with intrahippocampal stereotaxic injection of amyloid beta 1-42 (Aβ1-42). Intrahippocampal administration was applied to the CA1 area of hippocampus bilaterally (Aβ142 to the left side and PBS to the right side as control). Additionally, healthy male Sprague Dawley rats were utilized as naive group. Twenty days after surgery, biodistribution studies of 99mTc-Bioquin-HMPAO on animal model of AD and control group Susanne Granegger1, Lindsay Brammen2, Helmut Sinzinger1 1Institute ATHOS, Atherosclerosis Research, Vienna, Austria 2Vienna Medical University, Department of Nuclear Medicine, Vienna, Austria Elevated Lipoprotein(A) Impairs Platelet Radiolabeling Yield